Compare FGI & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FGI | SNSE |
|---|---|---|
| Founded | 1987 | 2005 |
| Country | United States | United States |
| Employees | N/A | 15 |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1M | 12.2M |
| IPO Year | 2022 | 2021 |
| Metric | FGI | SNSE |
|---|---|---|
| Price | $6.41 | $9.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $72.50 |
| AVG Volume (30 Days) | 18.2K | ★ 93.4K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $135,654,095.00 | N/A |
| Revenue This Year | $3.80 | N/A |
| Revenue Next Year | $6.26 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.66 | N/A |
| 52 Week Low | $2.28 | $5.00 |
| 52 Week High | $12.62 | $18.35 |
| Indicator | FGI | SNSE |
|---|---|---|
| Relative Strength Index (RSI) | 52.38 | 46.98 |
| Support Level | $6.02 | $9.35 |
| Resistance Level | $7.50 | $10.45 |
| Average True Range (ATR) | 0.46 | 0.98 |
| MACD | 0.04 | -0.19 |
| Stochastic Oscillator | 44.38 | 23.91 |
FGI Industries Ltd is a supplier of kitchen and bath products. The company is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. The company offers products that fall into four categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The company generates the majority of its revenue from the sale of Sanitaryware products. Geographically, the company generates the majority of its revenue from the United States, followed by Canada and Europe.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).